Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. - Wikidata - awgldk - TriplyDB

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

http://www.wikidata.org/entity/Q46549276

about

Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis Vedolizumab for induction and maintenance of remission in ulcerative colitis Histologic scoring indices for evaluation of disease activity in ulcerative colitis Interventions for induction of mucosal healing in ulcerative colitis Interventions for maintenance of mucosal healing in ulcerative colitis Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion Vedolizumab for the treatment of ulcerative colitis and Crohn's disease Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector.The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease Review of vedolizumab for the treatment of ulcerative colitis Integrin-based therapeutics: biological basis, clinical use and new drugs Optimal management of steroid-dependent ulcerative colitis Diagnostic imaging advances in murine models of colitis.Promising biological therapies for ulcerative colitis: A review of the literature Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease Patient considerations in the management of ulcerative colitis - role of vedolizumab Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature Shining a light on intestinal traffic Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA Summarizing historical information on controls in clinical trials Histologic scoring indices for evaluation of disease activity in ulcerative colitis.The safety of vedolizumab for the treatment of ulcerative colitis.Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.Leukocyte adhesion molecules in animal models of inflammatory bowel disease Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis.Preliminary in vivo efficacy studies of a recombinant rhesus anti-alpha(4)beta(7) monoclonal antibody.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.

P2860

Q24187044-3C47B35F-4255-4CE5-B81C-56AA8CA31AA7 Q24194423-71FF8B23-4588-478C-A056-BC486EB646F1 Q24194674-0EB79F29-F705-44B4-BF1A-D63A5AD06AE8 Q24200747-ACC218CF-E909-4E79-B85A-0E8640236E4C Q24200760-B0C7BEF7-3A0F-4606-8EDE-0A638C95159B Q24241123-80AF74CC-D3AB-4859-9D01-8154210FFFB7 Q24242681-86CB7A15-DC51-4F3D-A540-FA743B8A9DA3 Q24318873-3AAECF4D-7F09-4FA3-B30E-ECB68021EFC0 Q24611768-AB3FEB6C-C5B6-49A0-AF5B-DF47EB5EFF78 Q24630083-64C76501-9F2F-4C4D-8C80-C41E97A4E95B Q24812028-FB0F0743-2DD4-4BBB-8BBF-2FE17E991FDB Q26748626-27FE11EB-31FA-4397-9AFE-FB764481E128 Q26750456-475DE62A-2273-4971-8E36-C35A067CC978 Q26752768-EB7832F4-6096-471A-A1F7-7F5EC2B77146 Q26768259-74D60CB7-9A20-4CDD-A731-8EDD910225D4 Q26773026-2FBED970-0787-4851-A152-40AA2814FBD7 Q26773203-278B107A-3073-40B7-9441-3790D9557F36 Q26774583-CCB189D5-FFB3-44AE-A858-8DA496971475 Q26776139-04512F00-9FD2-45DB-B764-1EA9F3E6411A Q26785537-E92C0EB9-C84D-4B1B-835F-9B9972366ABA Q26786018-F1A507BE-4619-475D-882C-15A3230F046D Q26796432-FAEC59F0-6DF2-49DA-9ED3-9262E004028F Q26852514-912BEC4B-867F-4699-80EC-2ED1FADFB4F1 Q26863227-3CE07B5A-1276-41F3-AE9E-0ABFBC8588A0 Q26999705-DB896C27-6366-4EF2-83A6-C20899E86549 Q27005445-315D01CA-58D8-4CDF-85F9-500BD79826E1 Q27021612-A8D4D182-3564-4891-9E93-96BD8E89BBAA Q28080984-C98F6CA7-F849-4D31-95C7-1B673F029596 Q28083872-A1C336AD-342A-430F-906C-807CD4A41601 Q28084236-F2F6FB88-1F34-48B0-AC99-263E431E5D26 Q28660580-C63FCA72-56CE-4FB1-B71E-B69CCA65A967 Q29397593-2326FE71-1FE1-41D6-BCF7-3CC7F23F05D1 Q30234366-B1B3FD0E-2E19-4E49-AEAF-E7A0D67466F0 Q30235363-743DBBFE-F4BB-444C-A10D-8134E080D4D0 Q30248641-4F582493-AA09-4B0D-862C-5C77FF598A9C Q30300234-79B72CEA-EBA1-4CF7-859C-8DAEE782A0C8 Q30437758-79AAC2DC-CFD5-4E12-B1AE-C5C486FF1FE9 Q30439952-B15B90F9-AB0B-4978-A193-B508E9403F73 Q30491140-ECB70D7E-184C-4BFD-AB94-F0248416AE2C Q30902172-04167793-5894-47CF-B468-6100AB619A04

P2860

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

http://www.wikidata.org/entity/Q46549276

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@en

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@nl

type

label

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@en

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@nl

prefLabel

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@en

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@nl

P1433

Q46549276-CABBEFCC-4529-4903-871D-E454B2C9888C

P1476

Q46549276-19A82F0D-443C-4D52-A8CD-42F7646C6560

P2093

Q46549276-1A60B470-8F49-436B-B414-412ACFB7F80C

Q46549276-2265370D-9838-465C-A59F-A590FAC1A072

Q46549276-384A545F-2AC7-4906-AB86-314D51B8A3AE

Q46549276-4F98EE2A-E05F-48CF-8F03-49D3E1A3C442

Q46549276-5829CA9A-D4C8-4C13-B231-23F5D0AC18A4

Q46549276-7167D6D4-59EF-4FC1-8E22-7716900C747B

Q46549276-86358207-84FF-46D3-A13F-51A4B88AF714

Q46549276-8CF955F3-09ED-4F54-B365-7B06FDCCF59D

Q46549276-9CD5A3E6-1445-4E1C-8DB9-15490932DD0B

Q46549276-D1E9A234-F4CC-4A0B-8F28-FD1F7376DD10

P304

Q46549276-6EBBD42B-6A16-4377-B93B-09D2808F798D

P31

Q46549276-7EA30A62-9450-4777-A3A7-48AD8997A42C

P356

Q46549276-3E7E0705-8369-47BA-A0CD-78A59F4458A1

P407

Q46549276-A771B2E8-BC4A-4B82-BB28-300DE1CDED82

P433

Q46549276-A51160B1-C139-49BB-BF1E-968EBE3E7E53

P478

Q46549276-5E98473B-3C13-4770-B8FF-98FB6EA9DBDB

P50

Q46549276-2DE34D56-5074-4ED4-BA4F-D44E5F59B65D

Q46549276-FFEB4857-3928-4690-ABA0-78D6D14E97FA

P577

Q46549276-402D1BD4-2847-4DBA-AA94-DF7BDFF28886

P698

Q46549276-B00D54B9-EDFA-43BE-9AF1-9A11BE191F07

P921

Q46549276-1DDA4C67-D0B1-4394-BC04-67628EFAA875

P356

P1433

The New England Journal of Medicine

P1476

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

@en

P2093

A Hillary Steinhart

http://www.w3.org/2001/XMLSchema#string

Albert Cohen

http://www.w3.org/2001/XMLSchema#string

Gary Wild

http://www.w3.org/2001/XMLSchema#string

Gordon R Greenberg

http://www.w3.org/2001/XMLSchema#string

Irving H Fox

http://www.w3.org/2001/XMLSchema#string

John W D McDonald

http://www.w3.org/2001/XMLSchema#string

Margaret K Vandervoort

http://www.w3.org/2001/XMLSchema#string

Pierre Paré

http://www.w3.org/2001/XMLSchema#string

Rasha A Aguzzi

http://www.w3.org/2001/XMLSchema#string

Rejean Dubé

http://www.w3.org/2001/XMLSchema#string

P304

2499-2507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA042982

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

352

http://www.w3.org/2001/XMLSchema#string

P50

Richard N. Fedorak

Brian G. Feagan

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15958805

http://www.w3.org/2001/XMLSchema#string

P921